EUCTR2008-005427-28-ES进行中（未招募）不适用
Estudio fase IIIb, multicéntrico, con un período doble ciego controlado con placebo y aleatorizado de 12 semanas, seguido de una fase de extensión abierta para evaluar la seguridad y la eficacia de certolizumab pegol administrado a pacientes con artritis reumatoide activa. (A Phase IIIb, multicenter study with a 12-week double-blind, placebo-controlled, randomized period followed by an open-label, extension phase to evaluate the safety and efficacy of certolizumab pegol administered to patients with active rheumatoid arthritis). - Realistic
CB Pharma SA0 个研究点目标入组 1,048 人开始时间: 2009年1月26日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,048
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients must be at least 18 years old at the screening visit.
- •2. Patients must be able to understand the information provided to them and to give written Informed Consent.
- •3. Female patients must be either postmenopausal for at least one year, surgically incapable of childbearing, or effectively practicing an acceptable method of contraception (either oral/parenteral/implantable hormonal contraceptives, intrauterine device, or barrier and spermicide). Abstinence only is not an acceptable method. Patients must agree to use adequate contraception during the study and for 12 weeks after their last dose of CZP. Male patients must agree to ensure they or their female partner(s) uses adequate contraception during the study and for 12 weeks after the patient receives their last dose of CZP.
- •4. Patients must have a diagnosis of adult?onset RA of at least three months duration as defined by the 1987 American College of Rheumatology classification criteria.
- •5. Patients must have active RA disease as defined by:
- •? ?5 tender joints (28 joint count) at Screening and Baseline; and
- •? ?4 swollen joints (28 joint count) at Screening and Baseline; and
- •? ?10 mg/L CRP and/or ?28mm/hour ESR (Westergren)
- •6. Patients must have had an unsatisfactory response or intolerance to at least one traditional DMARD
- •7. Patients must be able and willing to comply with the requirements of the study protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients have a diagnosis of any other inflammatory arthritis (e.g., psoriatic arthritis or ankylosing spondylitis).
- •2. Patients have >3 arthroplasties due to RA and/or Steinbrocker IV functional capacity.
- •3. Patients have a secondary, non?inflammatory type of arthritis (e.g., osteoarthritis or fibromyalgia) that in the Investigator?s opinion is symptomatic enough to interfere with evaluation of the effect of study drug on the patient?s primary diagnosis of RA.
- •4. Patients have a history of an infected joint prosthesis at any time with that prosthesis still in situ.
- •5. Patients have received any of prohibited medication as detailed in the protocol.
- •6. Patients have received any experimental non?biological therapy, within or outside of a clinical study in the past three months or within 5 half-lives prior to Baseline visit (whichever is longer).
- •7. Patients have received any experimental biological agent within or outside of a clinical study in the past three months or within 5 half-lives prior to Baseline (whichever is longer).
- •8. Patients have received any biological therapy for RA within two months prior to Baseline visit, except for etanercept or anakinra for which a one month washout prior to baseline visit is acceptable.
- •9. Patients having discontinued or discontinuing biological therapy for their RA have had a severe hypersensitivity reaction or an anaphylactic reaction to more than 1 different biologic agent.
- •10. Patients have received treatment with more than 2 anti-TNF agents prior to enrollment in this study.
- •11. Patients have received treatment with rituximab and/or abatacept.
- •12. Female patients who are breast-feeding, pregnant, or plan to become pregnant during the study or within twelve weeks following last dose of study drug.
- •13. Patients with a history of chronic infection (more than 4 episodes requiring antibiotics/antivirals during the preceding year), recent serious or life?threatening infection within 6 months (including herpes zoster), or any current sign or symptom that may indicate an infection.
- •14. Patients with active TB (or history of active TB), positive chest X?ray for TB, or positive (defined as induration of ? 5mm) PPD skin test or patients having close contact with an individual with active TB. Patients having a PPD skin test ? 5 mm can enter the study, provided that active TB is excluded and provided that they are adequately treated for latent TB (e.g., isonicotinic acid hydrazide [INH therapy] for 9 months [with vitamin B6]) and provided that treatment is initiated at least 1 month prior to first administration of CZP.
- •15. Patients at a high risk of infection (e.g., leg ulcers, indwelling urinary catheter and persistent or recurrent chest infections and patients who are permanently bedridden or wheelchair bound).
- •16. Patients with a history of a lymphoproliferative disorder including lymphoma or signs and symptoms suggestive of lymphoproliferative disease.
- •17. Patients with concurrent acute or chronic viral hepatitis B or C.
- •18. Patients with known human immunodeficiency virus (HIV) infection.
- •19. Patients receiving any vaccination (live or attenuated) within eight weeks prior to baseline (e.g., parenteral influenza and pneumococcal vaccines are allowed, but nasal influenza vaccine is not).
- •20. Concurrent malignancy or a history of malignancy (other than carcinoma of the cervix or basal cell carcinoma successfully treated more than five years prior to screening).
- •21. Patients with a current or rece
研究者
相似试验
进行中（未招募）
1 期
Estudio en fase IIIb, multicéntrico, comparado con grupo de control, doble ciego, aleatorizado y de dos brazos, con evaluaciones mensuales por resonancia magnética y biomarcadores para evaluar la eficacia, la seguridad y la tolerabilidad de Rebif New Formulation (IFN beta-1a) en pacientes con esclerosis múltiple remitente-recurrente.A two-arm, randomized, double-blind, control group-compared, multicenter, phase IIIb study with monthly MRI and biomarker assessments to evaluate the efficacy, safety, and tolerability of Rebif® New Formulation (IFN-beta-1a) in subjects with relapsing remitting multiple sclerosis. - IMPROVE (Investigating MRI Parameters with Rebif® imprOVEd formulation)Relapsing remitting Multiple SclerosisMedDRA version: 9.0Level: PTClassification code 10063399EUCTR2006-003037-32-ESMerck Serono International SA
进行中（未招募）
1 期
Estudio fase IIIb, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de 2 periodos cruzados, para evaluar el efecto de indacaterol (150 µg o.d.), en pacientes con enfermedad pulmonar obstructiva crónica (EPOC) de moderada a grave que realicen ejercicios de resistencia.Enfermedad Pulmonar Obstructiva Crónica (EPOC) de moderada a graveMedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2008-008748-26-ESovartis Farmacéutica S.A.
进行中（未招募）
1 期
Estudio en fase III, multicéntrico, doble-ciego, aleatorizado, controlado con placebo de Epratuzumab en pacientes con crisis agudas severas de Lupus Eritematoso Sistémico excluyendo los sistemas renal o neurológico. - Estudio de Fase III de Epratuzumab en crisis agudas severas de lupus eritematoso sistémicoEUCTR2005-000705-59-ESImmunomedics, Inc.510
进行中（未招募）
不适用
Estudio en fase III, multicéntrico, doble-ciego, aleatorizado, controlado con tratamiento activo, con grupos paralelos, de no inferioridad, comparando 150 mg de Risedronato Mensual con 5mg de Risedronato Diario en el tratamiento de la osteoporosis postmenopausica evaluado a 12 y 24 meses. 2005032 (EFC6062) (HMR4003K/3001) - MERIT-OPmujeres con osteoporosis postmenopáusica.MedDRA version: 7.0Level: PTClassification code 10031285EUCTR2005-002785-10-ESProcter & Gamble Pharmaceuticals Inc1,068
进行中（未招募）
1 期
Estudio de Fase IIIb, multicéntrico, de 52 semanas de duración, aleatorizado, ciego, doble enmascarado, de grupos paralelos y de eficacia que compara el efecto de indacaterol 150 µg o.d. inhalado frente a tiotropio 18 µg o.d. inhalado en la función pulmonar, la tasa de exacerbaciones y resultados relacionados en pacientes con EPOC. - INVIGORATEEUCTR2008-007944-33-ESovartis Farmacéutica